

Unexpected Increased Platelet Count in an Acute Myeloid Leukemia Patient

Malte Hannich,^{a,b,c} Uwe Grunwald,^d Karoline Ehlert,^e Matthias Nauck,^a and Carlo Zaninetti^{b,*}

^aInstitute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany; ^bInstitute of Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany; ^cDepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany; ^dInternal Medicine C, Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany; ^eDepartment of Pediatric Hematology/Oncology, Children's Hospital, University Medicine Greifswald, Greifswald, Germany.

*Address correspondence to this author at: Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Sauerbruchstrasse, 17475 Greifswald, Germany. Tel 03834 86-19505; e-mail carlo.zaninetti@med.uni-greifswald.de.

CASE DESCRIPTION

A 2-year-old male patient had received a diagnosis of acute myeloid leukemia (subtype: acute myeloblastic leukemia with minimal maturation according to the French-American-British classification) (1) with a high genetic risk profile [i.e., monosomy 7, t(3;17)]. The child had initially undergone 2 courses of chemotherapy with sequential high-dose cytarabine and mitoxantrone. Because of an early relapse, allogeneic stem cell transplantation was planned, and the patient received a preparative chemotherapy regimen with fludarabine, treosulfan, thiotepa, and antithymocyte globulin. Because of an expected chemotherapy-related worsening of the pre-existing, disease-related thrombocytopenia, strict monitoring of the platelet count was started. In this context, the patient came to the attention of the laboratory due to challenges associated with measurement and interpretation of automated platelet counts.

A complete blood count prior to initiation of chemotherapy showed leukopenia [white blood cells (WBCs), $0.05 \times 10^9/L$; reference interval 6–17.5], normocytic anemia (hemoglobin, 8.38 g/dL; reference interval: 10.5–13), and moderate thrombocytopenia (platelets, $63 \times 10^9/L$; reference interval: 150–530). The hemolysis-icterus-lipemia index (reference interval: 1–8) gave a value of 4 for hemolysis and 1 each for bilirubin and lipemia; therefore, only a moderate influence due to hemolysis could be assumed. The macroscopic examination of the patient specimen also showed no abnormalities. After chemotherapy initiation, the automated hematology analyzer (Sysmex XN-20) produced very different platelet count results depending on the instrument measurement mode of operation. The platelet count increased to $361 \times 10^9/L$ when measured by impedance [platelet count-impedance (PC-I)]; $536 \times 10^9/L$ when measured optically (PC-O) and $156 \times 10^9/L$ when measured with fluorescence (PC-F). Because of the improbable kinetics of the platelet count data, a manual count was performed on the same specimen by phase-contrast microscopy using a Burkert chamber. Using this approach, the platelet count was $70 \times 10^9/L$, consistent with a moderate thrombocytopenia and in agreement with the prechemotherapy platelet count of $63 \times 10^9/L$ (Table 1). Compared to the evaluation prior to chemotherapy initiation, the hemolysis index increased from 4 to 6. In addition, a remarkable dark red staining of the blood sample, indicating hemolysis, was apparent on the macroscopic examination. Concomitantly, the systematic evaluation of the May-Gruenwald-Giemsa-stained peripheral blood smear by light microscopy showed the presence of abundant white cell debris, compatible with chemotherapy-induced tumor cell lysis, which were mostly in the size range of blood platelets (Fig. 1A–E). In addition, a substantial red blood cell (RBC) anisopoikilocytosis with fragments and typical microspherocytes of similar dimensions was apparent (Fig. 1C–E).

QUESTIONS TO CONSIDER

1. Which automated methods are available for platelet count, and which one shows the highest analytical inaccuracy?
2. Which factors can influence the different platelet measuring techniques and why?
3. Which phenomenon might cause a sudden increase of the platelet count after the start of chemotherapy?

Table 1. Platelet counts prior to and after initiation of chemotherapy.

	Platelet count ($\times 10^9/L$) [reference interval: 150–530]					HIL index (Hemolysis) ^b [range: 1–8]	LDH (U/L) [reference interval: 155–395]	Hb (g/dL) [reference interval: 10.5–13]	WBC ($\times 10^9/L$) [reference interval: 6–17.5]
	Automated								
	PC-I	PC-O	PC-F	FACS	Manual ^a				
Prechemotherapy									
Day 0	63	—	—	—	—	4	1895.62	8.38	0.05
Postchemotherapy									
Day +2	361	526	156	68	70	6	2159.57	10.47	0.02
Day +16	682	707	246	150	150	5	—	10.8	0.03
Day +19	461	580	168	80	75	4	1619.68	11.12	0.04

Abbreviations: FACS, fluorescence-activated cell sorting (i.e., reference method for platelet counting using a specific fluorochrome-conjugated monoclonal antibody anti-CD61); HIL, hemolysis-icterus-lipemia; LDH, lactate dehydrogenase; Hb, hemoglobin.
^aObtained by phase-contrast microscopic method using a Burker chamber.
^bHemolysis index obtained on the Siemens Dimension Vista.

Continued on the next page....




Fig. 1. Blood cell morphology on the peripheral blood smear by light microscopy and PC-F scattergram on day +2 after chemotherapy initiation. (A) Cell debris of different sizes and shapes (denoted by arrows) surrounded by normal erythrocytes and platelets. (B) Amorphous basophilic material, likely containing residual granule structures and possible remnants of disrupted cells with vacuoles (inset). (C–E and inset) Together with platelets showing normal size and granulation (P), erythrocytic fragments (F), microspherocytes (M), and cell debris (arrows) in the platelet size range are apparent. Scale bars correspond to 10 μm. (F) PC-F scattergram of the patient sample obtained on day +2 with a measured platelet count of $156 \times 10^9/\text{L}$. The dark blue cloud is the suspected cell debris population; the turquoise cloud is the suspected platelet population. (G) Manually gated PC-F scatter gram corresponding to a platelet count of $69 \times 10^9/\text{L}$. Color figure available at <https://academic.oup.com/clinchem>.

REFERENCE

1. Bain BJ. Blood cells: a practical guide. 6th Ed. Hoboken (NJ): Wiley; 2022.

Final Publication and Comments

The final published version with discussion and comments from the experts will appear in the July 2025 issue of *Clinical Chemistry*. To view the case and comments online, go to <https://academic.oup.com/clinchem/issue/71/7> and follow the link to the Clinical Case Study and Commentaries.

Educational Centers

If you are associated with an educational center and would like to receive the cases and questions 1 month in advance of publication, please email clinchemed@myadlm.org.

All previous Clinical Case Studies can be accessed and downloaded online at <https://www.myadlm.org/science-and-research/clinical-chemistry/clinical-case-studies>.

ADLM (formerly AACC) is pleased to allow free reproduction and distribution of this Clinical Case Study for personal or classroom discussion use. When photocopying, please make sure the DOI and copyright notice appear on each copy.

ADLM (formerly AACC) is a leading professional society dedicated to improving healthcare through laboratory medicine. Its nearly 10,000 members are clinical laboratory professionals, physicians, research scientists, and others involved in developing tests and directing laboratory operations. ADLM brings this community together with programs that advance knowledge, expertise, and innovation. ADLM is best known for the respected scientific journal *Clinical Chemistry* and the world's largest conference on laboratory medicine and technology. Through these and other programs, ADLM advances laboratory medicine and the quality of patient care.